IDEAYA Biosciences (NASDAQ:IDYA) Given “Outperform” Rating at Royal Bank Of Canada

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report)‘s stock had its “outperform” rating reissued by stock analysts at Royal Bank Of Canada in a research report issued on Tuesday, Benzinga reports. They presently have a $45.00 price target on the stock. Royal Bank Of Canada‘s target price would suggest a potential upside of 51.66% from the stock’s previous close.

IDYA has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Thursday, October 15th. Wedbush lifted their price objective on shares of IDEAYA Biosciences from $60.00 to $63.00 and gave the company an “outperform” rating in a research note on Wednesday, November 4th. Stifel Nicolaus initiated coverage on shares of IDEAYA Biosciences in a report on Wednesday, October 14th. They issued a “buy” rating and a $48.00 price objective on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Finally, William Blair began coverage on IDEAYA Biosciences in a report on Friday, October 16th. They issued an “outperform” rating for the company. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, IDEAYA Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.55.

Get Our Latest Stock Analysis on IDYA

IDEAYA Biosciences Stock Performance

Shares of NASDAQ IDYA opened at $29.67 on Tuesday. The business has a 50-day simple moving average of $35.28 and a two-hundred day simple moving average of $33.88. The company has a market cap of $2.87 billion, a PE ratio of -6.98 and a beta of 0.08. IDEAYA Biosciences has a fifty-two week low of $26.81 and a fifty-two week high of $42.68.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.04). IDEAYA Biosciences had a negative net margin of 1,157.18% and a negative return on equity of 39.78%. The company had revenue of $10.24 million for the quarter, compared to analyst estimates of $7.58 million. During the same quarter in the previous year, the company posted $1.33 EPS. The company’s revenue for the quarter was up 14.6% compared to the same quarter last year. On average, sell-side analysts predict that IDEAYA Biosciences will post -4.63 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEAYA Biosciences

In other news, CEO Yujiro Hata sold 26,338 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total value of $985,304.58. Following the transaction, the chief executive officer owned 690,695 shares in the company, valued at $25,838,899.95. This trade represents a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On IDEAYA Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of IDYA. Quantbot Technologies LP acquired a new stake in IDEAYA Biosciences in the 2nd quarter valued at about $43,000. Sterling Capital Management LLC increased its holdings in shares of IDEAYA Biosciences by 20.5% in the third quarter. Sterling Capital Management LLC now owns 1,873 shares of the company’s stock valued at $72,000 after purchasing an additional 319 shares during the last quarter. Nykredit A S acquired a new stake in shares of IDEAYA Biosciences in the second quarter valued at approximately $76,000. Fifth Third Bancorp purchased a new position in IDEAYA Biosciences during the first quarter worth approximately $84,000. Finally, GAMMA Investing LLC lifted its position in IDEAYA Biosciences by 79.0% during the third quarter. GAMMA Investing LLC now owns 2,315 shares of the company’s stock worth $89,000 after buying an additional 1,022 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

About IDEAYA Biosciences

(Get Free Report)

IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.

Recommended Stories

Analyst Recommendations for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.